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Purpose: Neurodegenerative diseases and neurotraumas typically result in apoptosis of specific neurons leading to the
pathology observed during the disease state. Existing treatments target the symptoms instead of preventing the death of
these neurons. Although neuroprotective drugs should be useful as a treatment to prevent further loss of neurons,
efficacious  molecules  are  lacking.  FK506  (tacrolimus),  a  widely  used  immunosuppressant  drug,  has  significant
neuroprotective and neuroregenerative properties throughout the central nervous system, including the eye. FK506
achieves these properties through interaction with FK506 binding proteins (FKBP), including FK506 binding protein 51
(FKBP51). In this study, we examine the effects of FKBP51 as a neuroprotective agent on a neuronal cell line.
Methods: We cultured 661w cell cultures with or without FK506, or stably transfected them with an FKBP51 expression
vector. These cells were then exposed to the apoptosis-inducing agent staurosporine. Cell viability was determined using
a calcein AM/propidium iodide assay. Protein levels and activation of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) were determined by western immunoblot analysis.
Results:  FKBP51  overexpression  significantly  protected  661w  cell  cultures  from  staurosporine-induced  apoptosis.
FKBP51 overexpression also significantly increased NF-κB p65 protein levels and activated NF-κB p65. FK506 treatment
significantly protected 661w neuronal cultures from staurosporine-induced apoptosis. FK506 increased FKBP51, NF-κB
p65, and levels of activated NF-κB p65 protein.
Conclusions: These results suggest that FKBP51 protects 661w cell cultures from apoptosis induced by staurosporine.
Additionally, FK506 protected 661w cell cultures from apoptosis and displayed a mechanism similar to that of FKBP51
overexpression. Both FK506 and FKBP51 appear to act through activation of NF-κB p65 protein, suggesting a common
pathway for neuroprotection. These findings implicate FKBP51 as a protein important to neuronal cell culture survival.
FKBP51 may be a potential therapeutic drug target for preventing the neurodegeneration and neurotrauma that occur
during neurodegenerative diseases.
Neurodegenerative diseases such as Alzheimer disease,
Parkinson disease, and glaucoma affect the lives of millions
and  are  increasing  in  prevalence  due  to  the  progressive
increase in human lifespan [1]. Each year, over 3 million
people  worldwide  die  from  neurologic  disorders  such  as
Alzheimer and Parkinson disease [2]. Typical treatments for
neurologic disorders specifically target treating the symptoms
of each individual disease and are not directed to intervening
in the disease process. However, it is known that apoptosis
accounts  for  most  neuronal  cell  death  during  neurologic
disorders  [3].  This  similarity  provides  hope  that
neuroprotectant intervention could be uniformly beneficial to
several  neurodegenerative  disorders;  however,  efficacious
neuroprotectants are currently unavailable [4].
FK506 (tacrolimus) exhibits significant neuroprotective
and  neuroregenerative  properties  in  several  forms  of
neurotrauma,  including  optic  nerve  crush,  traumatic  brain
injury, brain ischemia, sciatic nerve injury, and focal and
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global  ischemia  [5-8].  This  protection  is  not  limited  to
neurons; it extends to glia cells within the brain and several
other  organs  [9].  These  characteristics  of  FK506  make  it
potentially  useful  for  neuroprotection;  however,  FK506
produces calcineurin-induced immunosuppression by binding
FK506 Binding Protein 12 (FKBP12), which can increase the
incidence  of  cancer  [10,11].  FK506  was  found  to  be
equipotent in protecting cells lacking FKBP12 (U251 human
glioma), compared to cells expressing FKBP12 (SH-SY5Y
human neuroblastoma) [12]. Furthermore, FK506 also was
found to protect neurons in FKBP12 knockout mice [13].
FK506  drug  analogs,  such  as  GPI-1046,  which  function
independently of FKBP12, were shown to be neuroprotective
[12,14].  However,  not  all  FK506  downstream  signaling
pathways have been defined. FK506 interacts through several
binding  proteins,  leading  to  several  neuroprotective  and
neuroregenerative traits devoid of calcineurin inhibition [15].
Characterization  of  these  signaling  pathways  would  be
advantageous to treating neurodegenerative diseases without
systemic immunosuppression.
FKBP51, an immunophilin that interacts with FK506, is
a potential neuroprotective agent for preventing apoptosis
during neurodegenerative disease and neurotrauma. FKBP51
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1172plays a significant role in the activation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB), an
important cell-survival protein. The activation of NF-κB is
initiated  through  the  degradation  of  the  the  inhibitory
molecule, IKappaB (IκB). This leads to the activation and
translocation  of  NF-κB  into  the  nucleus  to  initiate
transcription of several prosurvival proteins, growth factors,
and anti-apoptotic proteins. IκB is ubiquitinated through the
serine/thereonine kinase, IKappaB Kinase (IKK), leading to
the degradation of IκB through a proteosome. FKBP51 is an
important cofactor of the catalytic subunit (IKKα) of IKK
[16].  Overexpression  of  FKBP51  has  been  shown  to
upregulate NF-κB protein levels in hematopoietic cells [17].
This  suggests  a  new  potential  neuroprotective  and
regenerative mechanism of FKBP51 [18]. Furthermore, NF-
κB  regulates  the  transcription  of  several  anti-apoptotic
proteins,  including  BCL-2  [19].  In  a  melanoma  cell  line,
siRNA-mediated  reduction  of  FKBP51  protein  levels
decreased  expression  of  NF-κB  and  increased  IκBα  and
IκBβ  protein  levels  [20].  In  UT7  cells,  FKBP51
overexpression increased the protein levels of NF-κB p65 and
NF-κB p50, and decreased the protein levels of IκBα [17].
Sustained activation of NF-κB was neuroprotective against
glutamate-induced excitotoxicity in primary cortical neurons
[21].
FKBP51 is a potential neuroprotective target; however,
it  is  unclear  if  FKBP51  plays  a  neuroprotective  role.
Currently,  we  are  testing  the  hypothesis  that  increases  in
FKBP51 protein levels decrease 661w neuronal cell culture
death  in  reaction  to  the  apoptosis-inducing  agent
staurosporine [22-24]
METHODS
661w cell culture: The 661w cells were derived from a murine
retinal  tumor  (these  have  been  shown  to  have  the  same
relevant  cellular  and  biochemical  characteristics  of  cone
photoreceptor neurons [25]). The 661w cells were grown in
Dulbecco’s  modified  Eagle’s  medium  (DMEM,  cat  no.
23700–040;  Invitrogen-Gibco,  Grand  Island,  NY),
supplemented with 10% heat-inactivated fetal bovine serum
(cat no. 26140–079; Invitrogen-Gibco), 100 U/ml penicillin,
and 100 mg/ml streptomycin (Fisher Scientific, Pittsburgh,
PA). The 661w cells were cultured at 37 °C in 5% CO2 and
air for all experiments.
Stable transfection: The pCL-neo-FKBP51 overexpression
vector and parental control pCl-neo vector were a kind gift
from Dr. Marc B. Cox, University of Texas El Paso, El Paso,
TX. Vectors were reconstituted in sterile Tris/EDTA buffer
and transformed into DH5α E. coli. Competent bacteria were
selected using ampicillin LB plates. Colonies that produced
the highest levels of vectors were selected through miniprep.
Maxipreps were performed using a CsCl gradient. Vectors
were rehydrated in sterile TE buffer and maintained at −20 °C.
The 661w neuronal cell cultures (passage 6) were seeded
in 100 mm dishes and grown with complete DMEM. After 24
h,  the  cell  cultures  were  transfected  through  a  lipophilic
method  (Metafectene  Pro;  Biontex,  Toulouse,  France),  as
instructed by the manufacturer. After an additional 24 h, 2 mg/
ml of G418 were added to kill cells that did not incorporate
the vectors. Cells were maintained on 0.2 mg/ml G418 and
grown to a maximum 15 passages.
Western blot analysis: Cultured cells, from cells grown at
60%–80% confluence, were isolated and lysed as previously
described  [26].  Protease  inhibitors  (1  mM  Dithiothreitol
[DTT] and 500 µM Phenylmethanesulfonyl fluoride [PMSF])
were added. Cells were harvested at 60%–80% confluence.
Protein  concentrations  were  determined  using  Bio-Rad
Bradford  Protein  Assay  (500–0006;  Bio-RaD,  Bio-Rad
Laboratories, Hercules, CA). Samples of protein (25 μg) were
run on a sodium dodecyl sulfate 7.5% polyacrylamide gel and
immunoblotted  according  to  previous  published  methods
[27-29].  Briefly,  the  separated  protein  was  transferred  to
0.45  μm-supported  nitrocellulose  membranes  (162–0094;
BioRad) and blocked with 7.5% nonfat dry milk in Tris-
buffered saline with Tween. The following primary antibodies
were  used:  mouse  anti-FKBP51  (610582,  1:500;  BD
Transduction Laboratories, Lexington, KY); mouse anti-NF-
Figure 1. FK506 (tacrolimus) binding
protein 51 is expressed in rat retina and
brain. Tissues were extracted from an
adult  Sprague  Dawley  rat  and  the
protein was isolated. Tissue lysates (50
μg) were added to each lane. Western
blot analysis detected the protein in the
brain,  heart,  lung,  liver,  kidney,  and
retina.
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1173κB (SC-8008, 1:500; Santa Cruz, Santa Cruz, CA); mouse
anti-GAPDH  (P04406,  1:1000;  Millipore,  Billerica,  MA);
rabbit anti-phospho-NF-κB (3033, 1:500; Cell Signaling, Cell
Signaling Technology, Inc., Danvers, MA); and mouse anti-
β-tubulin (T0198, 1:1,000; Sigma, Sigma-Aldrich, St. Louis,
MO).  Primary  antibodies  were  incubated  and  rotated
overnight at 4 °C. Blots were washed for 30 min at room
temperature. Prior to the addition of secondary antibodies
ECL-rabbit  IgG,  HRP-linked,  or  ECL-mouse  IgG,  HRP-
linked (NA9340 and NA9310, 1:10,000; GE, Piscataway, NJ)
for 30 min. Luminescence was detected using SuperSignal
West Dura (34075; Thermo Scientific, Waltham, MA) in the
BioRad  Molecular  Imager.  Densitometric  analysis  was
Figure 2. FK506 (tacrolimus) binding protein 51 overexpression increases protein levels of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), activated NF-κB, and decreased protein levels of inhibitory molecule, IKappaB (IκB). A: FK506 Binding Protein
51 (FKBP51) overexpression significantly increased NF-κB p65 and phospho NF-κB p65 protein levels while significantly decreasing
IκBα protein levels. The 661w neuronal cell culture—stably transfected with an FKBP51 expression vector—increased FKBP51 protein levels
fivefold, compared to the 661w neuronal cell culture stably transfected with the parental empty vector. (-) represents stably transfected empty
vector control cells and (+) represents stably transfected FKBP51 overexpression cells. B, C: The increase in FKBP51 expression caused a
significant increase in protein levels of NF-κB p65 and activated NF-κB p65 (NF-κB p65: n=6, *p=0.002; phospho NF-κB p65: n=6, *p=0.002).
D: The increase in FKBP51 expression caused a significant decrease in protein levels of IκBα (IκBα: n=3, *p=0.044). The loading controls
were β-tubulin for IκBα and NF-κB p65, while GAPDH was used for FKBP51 and for activated NF-κB p65. Significance was obtained through
one-way ANOVA (ANOVA) and the Mann–Whitney test. Error bars represent SEM.
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tubulin were used as loading controls.
Calcein-acetomethoxy/propidium iodide cell-survival assay:
Cell  viability  was  determined  using  a  calcein/propidium
iodide  (cat.  no.  C3099;  Invitrogen-Molecular  Probes,
Carlsbad, CA) dual-staining assay. The cell cultures were
treated with or without 100 nM–10 μM staurosporine, an
apoptosis-inducing agent [22-24], for 24 h (ALX-380–014-
M001; Enzo Life Sciences, Plymouth Meeting, PA). After
treatment,  the  culture  medium  was  removed,  and  the
coverslips were rinsed with 1× phosphate buffer saline (PBS).
Then, 1 μM calcein and 2 µg/ml propidium iodide in 2 ml 1×
PBS were added to each culture well. The culture dishes with
the cells were incubated at 37 °C for 60 min, and fluorescence
was  measured  (Microphot  FXA  digital  fluorescent
microscope; Nikon, Melville, NY).
Caspase-3  detection  assay:  Caspase-3  activity  was
determined using the SR-DEVD-FMK Caspase-3 detection
kit, Cell Technology Inc. (Mountain View, CA) following the
manufacturer’s protocol. Coverslips were coated with 10 μg/
ml Poly-D-Lysine for 60 min, washed, and then placed into
wells with 500 μl of DMEM. Either 10,000 empty vector or
FKBP51-overexpressing 661w cells were added to each well
and incubated for 24 h. Staurosporine or a vehicle was added
Figure 3. FK506 (tacrolimus) binding protein 51 overexpression protects 661w cell culture from staurosporine. A: The FK506 Binding Protein
51 (FKBP51) protein significantly protected the 661w neuronal cell culture from staurosporine-induced apoptosis. Cell survival was monitored
with a calcein-AM/propidium iodide cell-survival assay. The 661w neuronal cell cultures were stably transfected with either an FKBP51
expression vector or parental empty vector. Cells were treated with or without varying concentrations of staurosporine (10 nM, 100 nM, and
1 µM) for 24 h (scale bar=100 µm). B: FKBP51 overexpression significantly protected the 661w neuronal cell culture from staurosporine-
induced apoptosis at 100 nM (p=0.013) and 1 μM (p≤0.001) concentrations (n=3). Error bars represent SEM.
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or 1 μM for 6 h. Cells were washed three times with PBS.
Prepared caspase-3 detection reagent (300 μl) was added to
each well and incubated for 60 min. Cells were washed three
times with PBS and then inverted onto a slide with Fluorosave.
Images  were  taken  at  the  same  exposure  times  on  a
fluorescence microscope (Microphot FXA digital fluorescent
microscope;  Nikon).  Images  were  measured  for  intensity
using Image J software.
Statistical analysis: SigmaPlot 11.0 (Systat Software Inc., San
Jose, CA) was used to perform all statistical analyses. Results
were expressed as mean±standard error. Paired comparisons
were  analyzed  using  a  Mann–Whitney  U  test.  Multiple
comparisons  were  performed  using  a  one-way  ANOVA
(ANOVA) followed by a Mann–Whitney U test. Significance
was defined as a p value of ≤0.05.
RESULTS
FKBP51 expressed in rat retina and brain: An adult Sprague
Dawley rat was sacrificed and the brain, retina, heart, lung,
liver, and kidney were collected in HEPES buffer containing
protease inhibitors (1 mM DTT and 500 µM PMSF). Tissue
and cells were lysed using sonication. Fifty micrograms of
protein were added to each well. An anti-FKBP51 antibody
(Cat: 610582; BD Transduction Laboratories) was used to
Figure 4. FK506 (tacrolimus) treatment increases FK506 binding protein 51 (FKBP51) and nuclear factor kappa-light-chain-enhancer of
activated B (NF-kB) cell protein levels. A: Twenty-four hour FK506 treatments significantly increased protein levels of FKBP51 and NF-
κB in the 661w neuronal cell cultures. The 661w neuronal cell cultures were treated for 24 h with a vehicle—100 nM FK506, 1 μM FK506,
or 10 μM FK506. Cell lysate proteins (25 µg) were separated by sodium dodecyl sulfate PAGE (SDS–PAGE), transferred to membranes, and
immunoblotted for FKBP51, NF-κB, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The quantification of band intensity is
represented as a percentage of FKBP51 or NF-κB of its corresponding GAPDH control band on the same membrane. B: FK506 significantly
increased FKBP51 protein levels at a concentration of 10 μM (p=0.03), while 0.1 μM and 1 μM caused an increased in FKBP51 protein levels;
however, significance was not obtained (n=3). Error bars represent SEM C: Additionally, FK506 significantly increased NF-κB protein levels
at a concentration of 0.1 μM (p=0.004), while 1 μM and 10 μM caused larger increases in protein levels; however, significance was not
obtained (n=3 for each dose indicated).
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1176detect FKBP51 protein. FKBP51 was detected in all tissues
that were analyzed (Figure 1).
FKBP51 overexpression increased protein levels of NF-κB
and activated NF-κ and decreases protein levels of IκBα:
FKPB51 is expressed in many organs, including the retina
(Figure 1). We used western blot analysis to determine the
expression  of  FKBP51  and  the  potential  downstream
signaling molecules NF-κB p65 and phosphorylated NF-κB
Figure 5. The 1 μM FK506 (tacrolimus) treatment increases activation of the nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kB). A: The 1 μM FK506 treatment for 30 min significantly activated NF-κB protein in 661w neuronal cell cultures. These were treated
with 1 μM FK506 or the control (DMSO) for 30 min, 1 h, 2 h, or 4 h. Cell lysate proteins (25 ug) were separated by western immunoblot
analysis for phosphor-NF-κB and β-tubulin. The quantification of band intensity is represented as the percentage of phospho NF-κB of the
corresponding control (β-tubulin) band on the same membrane. B: The 1 μM FK506 significantly increased phospho NF-κB protein levels
(p=0.004) at 30 min, while phospho NF-κB protein levels returned to near basal levels within 2 h of FK506 treatment (n=6). Error bars represent
SEM.
Figure 6. FK506 (tacrolimus) protects 661w cell cultures from staurosporine-induced cell death. A: FK506 (1 μM) significantly protected
661w neuronal cell cultures from staurosporine-induced apoptosis. Cell survival was monitored with the calcein-AM/propidium iodide cell-
survival assay (scale bar=100 µm). The 661w neuronal cell cultures were treated with 1 μM FK506, with 1 μM staurosporine, with both 1
μM FK506 and 1 μM staurosporine, or with vehicle for 24 h. B: The 1 μM FK506 treatments significantly protected 661w neuronal cell
cultures from 1 μM staurosporine-induced apoptosis (p<0.001, n=3). Error bars represent SEM.
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1177(n=6).  FKBP51  was  overexpressed  fivefold  in  FKBP51
transfected cells, compared to cells transfected with the empty
vector  controls.  The  overexpression  of  FKBP51  also
increased protein levels of phosphorylated NF-κB p65 by
3.2±0.5 fold and NF-κB p65 by 18±14 fold. β-tubulin (IκBα
and NF-κB p65) or GAPDH (FKBP51 and phosphor NF-κB
p65) was used for normalization (Figure 2).
FKBP51 overexpression protected 661w cell culture from
staurosporine: We wanted to determine whether an increase
in FKBP51 protein would protect neuronal cell cultures from
staurosporine,  the  apoptosis-inducing  agent.  Cell  viability
was determined using calcein AM/propidium iodide double-
staining. In the absence of staurosporine, 99%–100% of the
FKBP51 and empty-vector transfected cells remained viable.
The addition of 10 nM staurosporine for 24 h did not induce
a significant level of apoptosis in either cell culture. FKBP51
cells had 98±0.02% viability, and 99±0.01% of empty vector
cells  survived.  In  contrast,  the  addition  of  100  nM
staurosporine  induced  cell  death  in  both  FKBP51-
overexpressing  and  empty-vector  cell  cultures.  However,
FKBP51  overexpression  significantly  protected  the  661w
neuronal cells from 100 nM staurosporine-induced apoptosis
(83±0.02%  viability  in  FKBP51  cells  versus  71±0.04%
viability in control cells, p=0.013). Furthermore, FKBP51
overexpression significantly protected the 661w neuronal cell
culture  from  the  24  h  of  1  μM  staurosporine-induced
apoptosis.  The  FKBP51  overexpression  significantly
protected the neuronal cells (62±0.03% viability in FKBP51
cells  versus  12±0.02%  viability  in  control  cells,  p≤0.001;
Figure 3).
FK506  treatment  increased  FKBP51  and  NF-κB  protein
levels: Western blot analysis was used to determine the protein
expression of FKBP51 and NF-κB p65 after 24 h of FK506
treatment (n=3). FK506 dose-dependently increased FKBP51
and NF-κB protein levels. FKBP51 was significantly elevated
with  10  μM  FK506  (p=0.023)  and  NF-κB  at  100  nM
(p=0.004).
All three concentrations of FK506 (0.1 μM, 1 μM, and
10 μM) increased FKBP51 protein expression by 1.36±0.3
fold,  2.7±0.9  fold,  and  2.6±0.4  fold,  respectively.
Furthermore, the same FK506 concentrations increased NF-
κB p65 protein levels by 1.58±0.1 fold, 2.42±0.21 fold, and
5.6±0.4 fold, respectively. GAPDH was used as an equal
loading  control  (Figure  4).  Additionally,  there  were  no
changes to phosphorylated NF-κB p65 protein levels when
analyzed during the 24 h treatment (unpublished data).
One micromole FK506 treatment increased activation of NF-
κB:  NF-κB  is  a  nuclear  transcription  factor  with  diverse
activities, including the regulation of cell survival [30]. The
majority, but not all, of the available research indicates that
NF-κB  increases  anti-apoptotic  actions  and  prevents  cell
death in various cells [31-33]. It would be helpful to determine
if FK506, like FKBP51, activates NF-κB, because it may be
a common downstream molecule activated by both FK506
and  FKBP51  to  achieve  neuroprotection.  Western
immunoblot  analysis  determined  that  the  FK506  (1  μM)
phosphorylates NF-κB p65 after 30 min, 1 h, 2 h, and and 4 h
(n=6 at each time point). FK506 significantly increased the
phosphorylation of NF-κB p65 2.2±0.5 fold (p=0.004) after
30 min. It was also determined that phosphorylated NF-κB
p65 returned to baseline after 1 h, 2 h, and 4 h. β-tubulin was
used as the equal-loading control. Therefore, the protein levels
of NF-κB p65 increased after 24 h of treatment, while the
phosphorylated form of NF-κB p65 increased sooner (Figure
5).
FK506  protected  661w  cell  cultures  from  staurosporine-
induced cell death: FK506 is neuroprotective against several
forms of toxicity as well as in several in vivo [5,6] and in vitro
models  [7,8].  Although  FK506  is  significantly
neuroprotective outside of the eye, we want to determine
whether FK506 protects ocular neuronal cell cultures from
staurosporine-induced-apoptosis.  The  661w  neuronal  cell
cultures were processed for determination of apoptosis using
calcein AM/propidium iodide double-staining [34] following
1 μM staurosporine and 1 μM FK506 treatments. Virtually all
661w neuronal cell cultures were alive when untreated or
treated  with  1  μM  FK506.  In  contrast,  when  the  661w
neuronal cell cultures were exposed to 1 μM staurosporine for
24  h,  only  28±0.05%  of  the  cell  cultures  survived.  The
addition of 1 μM FK506 significantly protected the 661w
neuronal cell cultures (p≤0.001) from 1 μM staurosporine-
induced apoptosis over the 24 h treatment, by increasing the
survival rate to 95±0.01 (p=012; Figure 6).
FKBP51 overexpression protected 661w cell culture from
staurosporine  induced  caspase-3  activation:  Apoptosis
accounts for most of the neuronal cell death observed during
neurologic disorders [3]. It would be advantageous to prevent
apoptosis  to  uniformly  treat  a  wide  range  of  neurologic
disorders.  Staurosporine  was  used  to  induce  apoptosis
[22-24]. We investigated whether an increase of FKBP51
protein  protected  against  caspase-3  activation,  a  common
marker of apoptosis. Six hours of staurosporine treatment was
used to induce a significant amount of caspase-3 activation.
FKBP51 overexpression significantly decreased the amount
of  caspase-3  activation  at  all  three  concentrations  of
staurosporine:  10  nM  (p=0.006),  100  nM  (p=0.001),  and
1 μM (p<0.001; Figure 7).
DISCUSSION
FKBP51  has  diverse  physiologic  functions.  FKBP51  is  a
chaperone  protein  that  aids  in  the  transport  of  several
hormones and hormone receptors. It is increased in several
forms of cancer. It may also be increased in prostate cancer
patients. This increase of FKBP51 is a suggested cause for
positive feedback from androgen and the androgen receptors.
This promotes cell survival and growth in these non-neuronal
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1178cells [35-37]. An increase in FKBP51 protein levels has been
Figure 7. FK506 binding protein 51 overexpression protects 661w
cell  culture  from  staurosporine-induced  caspase  3  activation.
Staurosporine treatments for 6 h significantly increased caspase 3
activation, a marker of apoptosis, in 661w cell culture. FKBP51
overexpression in 661w cell cultures significantly decreased caspase
3 activation during staurosporine treatments. Caspase 3 activity was
assayed using a colorimetric caspase 3 detection kit. Intensity was
measured using Image J. FKBP51 significantly protected against
caspase  3  activation  during  staurosporine  treatment  at  10  nM
(p=0.006,  n=3),  100  nM  (p=0.001,  n=3),  and  1  μM  (p<0.001).
Significance  was  obtained  through  ANOVA  (ANOVA)  and  the
Mann–Whitney test. Error bars represent SEM.
shown to cause resistance to chemotherapeutic agents that
induce apoptosis in cancerous tumors [35,38]. Even though
this is a disease state, in which homeostasis is out of balance,
it  would  be  advantageous  to  more  thoroughly  understand
whether  increases  in  FKBP51  activity  can  promote  cell
survival  and  growth.  In  neurons,  FKBP51  promotes
microtubule stability and elongation. FKBP51 works with
Hsp90 to bind phosphorylated tau [39]. FKBP51 catalyzes the
cis-trans  isomerization  of  the  peptidyl–prolyl  bonds  (the
PPIase reaction), allowing tau to be recycled. With a mutant
or defective FKBP51 molecule, the PPIase reaction will not
occur,  causing  an  accumulation  of  phosphorylated  tau
proteins, potentially leading to an Alzheimer disease-like state
[39].  Furthermore,  FKBP51  is  involved  in  several  cell-
signaling  pathways  that  promote  cell  survival  and
neuroregeneration  [16,40].  FKBP51’s  diverse  physiologic
functions, including its prosurvival properties, make it an
important molecule to continue researching.
In this study, we have shown that FKBP51 neuroprotects
661w neuronal cell lines from the apoptosis-inducing agent,
staurosporine. Even though FKBP51 has been well researched
for its protective properties outside of the central nervous
system, its protective properties within neurons need more
research  [16,17].  FKBP51’s  neuroprotective  efficacy  and
function  in  other  in  vitro  and  in  vivo  models  of  ocular
neurodegeneration need to be tested to determine its potential
for treating neurodegenerative diseases and neurotrauma. The
downstream molecules that FKBP51 interacts with appear to
be similar to those that interact with FK506. Furthermore, a
drug  that  targets  FKBP51  without  inhibiting  calcineurin
through  FK506  and  causing  systemic  immunosuppression
would be beneficial. A drug that is a potential candidate is
GPI1046.  GPI1046  is  an  FK506  analog,  a  non-
immunosuppressive immunophilin ligand that appears to have
the same neuroprotective properties [12]. GPI1046 displays
neurosurvival and regenerative activities in vivo and in vitro
[41,42].  Further  investigation  of  GPI1046  is  needed  to
determine its value not only as a neuroprotective molecule,
but also as an aid to characterizing immunophilins such as
FKBP51.
FKBP51  is  an  important  coactivator  of  the  NF-κB
signaling  pathway  [34].  NF-κB  has  both  detrimental  and
prosurvival effects in neurons. NF-κB activity still remains an
important signaling molecule to investigate. Many argue that
NF-κB has a large effect on prosurvival genes, supported by
the  finding  that  NF-κB  knockouts  are  lethal  during
development [30,43,44]. This present study demonstrates that
an increase of FKBP51 can increase protein levels and the
activation  of  NF-κB’s  major  subunit,  NF-κB  p65.
Interestingly, FK506’s effect on NF-κB in neurons is still
controversial [45,46]. Nevertheless, 1 μM of FK506 caused a
phosphorylation of NF-κB p65 in 661w neuronal cell cultures
after 30 min. The mechanism of this activation is still not
understood;  however,  it  may  occur  through  FKBP51.
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essential to FK506 phosphorylation of NF-κB p65.
In summary, we have shown that an increase of FKBP51
protein  protects  661w  neuronal  cell  cultures  from  the
apoptosis-inducing  agent  staurosporine.  Both  FK506  and
FKBP51  share  similar  downstream  signaling  molecules,
suggesting that utilization of FKBP51 by FK506. FKBP51 has
has  diverse  physiologic  functions  in  promoting  several
prosurvival pathways. A potential therapeutic intervention is
to increase the function of FKBP51, which could increase the
stability  and  duration  of  several  FKBP51  downstream
molecules to maintain or even increase cell survival.
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